Floatz logo

Uniprost

Pulmonary Fibrosis

United TherapeuticsSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
Acetylcysteine
Boehringer Ingelheim
Phase 3BB
Nintedanib
Boehringer Ingelheim
Phase 3BB
Admilparant
Bristol-Myers Squibb
Phase 3BB
Pirfenidone
Boehringer Ingelheim
Phase 2BB
Sildenafil
Alicia Gerke
Phase 3BB

View all 34 →

Same molecule, other indications

Uniprost is also rated in:

interstitial lung diseaseActive
BB
Indicative · Phase 3
64 / 100
View asset →
pulmonary hypertensionActive
B
Indicative · Phase 3
62 / 100
View asset →
idiopathic pulmonary fibrosisActive
B
Indicative · Phase 3
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →